CN113975367A - 一种红色零价单质纳米硒口服液及其制备方法和应用 - Google Patents
一种红色零价单质纳米硒口服液及其制备方法和应用 Download PDFInfo
- Publication number
- CN113975367A CN113975367A CN202110880225.0A CN202110880225A CN113975367A CN 113975367 A CN113975367 A CN 113975367A CN 202110880225 A CN202110880225 A CN 202110880225A CN 113975367 A CN113975367 A CN 113975367A
- Authority
- CN
- China
- Prior art keywords
- selenium
- zero
- valent
- nano
- oral liquid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000011669 selenium Substances 0.000 title claims abstract description 178
- 229910052711 selenium Inorganic materials 0.000 title claims abstract description 178
- 239000007788 liquid Substances 0.000 title claims abstract description 75
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 229940091258 selenium supplement Drugs 0.000 claims abstract description 184
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims abstract description 93
- 238000000855 fermentation Methods 0.000 claims abstract description 39
- 230000004151 fermentation Effects 0.000 claims abstract description 39
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims abstract description 38
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 35
- 235000006533 astragalus Nutrition 0.000 claims abstract description 24
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 claims abstract description 20
- 229960001471 sodium selenite Drugs 0.000 claims abstract description 20
- 235000015921 sodium selenite Nutrition 0.000 claims abstract description 20
- 239000011781 sodium selenite Substances 0.000 claims abstract description 20
- 241000894006 Bacteria Species 0.000 claims abstract description 19
- 235000014655 lactic acid Nutrition 0.000 claims abstract description 19
- 239000004310 lactic acid Substances 0.000 claims abstract description 19
- 238000000034 method Methods 0.000 claims abstract description 15
- 239000007864 aqueous solution Substances 0.000 claims abstract description 11
- 241000045403 Astragalus propinquus Species 0.000 claims abstract description 10
- 230000008569 process Effects 0.000 claims abstract description 9
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims abstract description 6
- 239000002994 raw material Substances 0.000 claims abstract description 5
- 241000186660 Lactobacillus Species 0.000 claims description 15
- 229940039696 lactobacillus Drugs 0.000 claims description 15
- 241001061264 Astragalus Species 0.000 claims description 14
- 238000002156 mixing Methods 0.000 claims description 14
- 210000004233 talus Anatomy 0.000 claims description 14
- 239000000243 solution Substances 0.000 claims description 13
- 239000002244 precipitate Substances 0.000 claims description 12
- 239000001963 growth medium Substances 0.000 claims description 10
- 238000009630 liquid culture Methods 0.000 claims description 8
- 230000036039 immunity Effects 0.000 claims description 6
- 230000001954 sterilising effect Effects 0.000 claims description 6
- 238000012258 culturing Methods 0.000 claims description 5
- 238000007710 freezing Methods 0.000 claims description 4
- 230000008014 freezing Effects 0.000 claims description 4
- 238000000227 grinding Methods 0.000 claims description 4
- 239000012535 impurity Substances 0.000 claims description 4
- 230000000813 microbial effect Effects 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 238000004659 sterilization and disinfection Methods 0.000 claims description 4
- 238000009423 ventilation Methods 0.000 claims description 4
- 238000005406 washing Methods 0.000 claims description 4
- 108090000790 Enzymes Proteins 0.000 claims description 3
- 102000004190 Enzymes Human genes 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 238000011081 inoculation Methods 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims description 2
- 238000003973 irrigation Methods 0.000 claims description 2
- 230000002262 irrigation Effects 0.000 claims description 2
- 125000003748 selenium group Chemical group *[Se]* 0.000 claims description 2
- 238000012859 sterile filling Methods 0.000 claims description 2
- 230000002708 enhancing effect Effects 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 abstract description 6
- 231100000419 toxicity Toxicity 0.000 abstract description 6
- 230000001988 toxicity Effects 0.000 abstract description 6
- 230000009467 reduction Effects 0.000 abstract description 5
- 201000011510 cancer Diseases 0.000 abstract description 4
- 230000004071 biological effect Effects 0.000 abstract description 3
- 239000011159 matrix material Substances 0.000 abstract description 3
- 108010024636 Glutathione Proteins 0.000 abstract description 2
- 229960003180 glutathione Drugs 0.000 abstract description 2
- 238000009098 adjuvant therapy Methods 0.000 abstract 1
- 230000002349 favourable effect Effects 0.000 abstract 1
- 239000000284 extract Substances 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 11
- 230000000052 comparative effect Effects 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 241000229143 Hippophae Species 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000001914 filtration Methods 0.000 description 6
- MCAHWIHFGHIESP-UHFFFAOYSA-L selenite(2-) Chemical compound [O-][Se]([O-])=O MCAHWIHFGHIESP-UHFFFAOYSA-L 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 235000003145 Hippophae rhamnoides Nutrition 0.000 description 4
- 240000007651 Rubus glaucus Species 0.000 description 4
- 235000011034 Rubus glaucus Nutrition 0.000 description 4
- 235000009122 Rubus idaeus Nutrition 0.000 description 4
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 4
- 235000018417 cysteine Nutrition 0.000 description 4
- 238000004108 freeze drying Methods 0.000 description 4
- 150000004676 glycans Chemical class 0.000 description 4
- QYSGYZVSCZSLHT-UHFFFAOYSA-N octafluoropropane Chemical compound FC(F)(F)C(F)(F)C(F)(F)F QYSGYZVSCZSLHT-UHFFFAOYSA-N 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 229940082569 selenite Drugs 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 108010059892 Cellulase Proteins 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 235000003935 Hippophae Nutrition 0.000 description 3
- 239000001888 Peptone Substances 0.000 description 3
- 108010080698 Peptones Proteins 0.000 description 3
- 108010059820 Polygalacturonase Proteins 0.000 description 3
- 235000015278 beef Nutrition 0.000 description 3
- 229940106157 cellulase Drugs 0.000 description 3
- 108010093305 exopolygalacturonase Proteins 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 235000019319 peptone Nutrition 0.000 description 3
- 231100000572 poisoning Toxicity 0.000 description 3
- 230000000607 poisoning effect Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000009636 Huang Qi Substances 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 235000012907 honey Nutrition 0.000 description 2
- 238000002354 inductively-coupled plasma atomic emission spectroscopy Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000002386 leaching Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000003607 modifier Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000001814 pectin Substances 0.000 description 2
- 229920001277 pectin Polymers 0.000 description 2
- 235000010987 pectin Nutrition 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- -1 selenate ions Chemical class 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- FDKWRPBBCBCIGA-REOHCLBHSA-N (2r)-2-azaniumyl-3-$l^{1}-selanylpropanoate Chemical compound [Se]C[C@H](N)C(O)=O FDKWRPBBCBCIGA-REOHCLBHSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- FDKWRPBBCBCIGA-UWTATZPHSA-N D-Selenocysteine Natural products [Se]C[C@@H](N)C(O)=O FDKWRPBBCBCIGA-UWTATZPHSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010068370 Glutens Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- 244000241838 Lycium barbarum Species 0.000 description 1
- 235000015459 Lycium barbarum Nutrition 0.000 description 1
- 244000241872 Lycium chinense Species 0.000 description 1
- 235000015468 Lycium chinense Nutrition 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- XDSSPSLGNGIIHP-VKHMYHEASA-N Se-methyl-L-selenocysteine Chemical compound C[Se]C[C@H]([NH3+])C([O-])=O XDSSPSLGNGIIHP-VKHMYHEASA-N 0.000 description 1
- 206010039921 Selenium deficiency Diseases 0.000 description 1
- RJFAYQIBOAGBLC-BYPYZUCNSA-N Selenium-L-methionine Chemical compound C[Se]CC[C@H](N)C(O)=O RJFAYQIBOAGBLC-BYPYZUCNSA-N 0.000 description 1
- RJFAYQIBOAGBLC-UHFFFAOYSA-N Selenomethionine Natural products C[Se]CCC(N)C(O)=O RJFAYQIBOAGBLC-UHFFFAOYSA-N 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000021312 gluten Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002736 metal compounds Chemical class 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229940005981 selenite ion Drugs 0.000 description 1
- 150000003342 selenium Chemical class 0.000 description 1
- ZKZBPNGNEQAJSX-UHFFFAOYSA-N selenocysteine Natural products [SeH]CC(N)C(O)=O ZKZBPNGNEQAJSX-UHFFFAOYSA-N 0.000 description 1
- 235000016491 selenocysteine Nutrition 0.000 description 1
- 229940055619 selenocysteine Drugs 0.000 description 1
- 229960002718 selenomethionine Drugs 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000002351 wastewater Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/011—Hydrolysed proteins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
- A23L33/165—Complexes or chelates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
- A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
- A61L2/0023—Heat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y40/00—Manufacture or treatment of nanostructures
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P3/00—Preparation of elements or inorganic compounds except carbon dioxide
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2202/00—Aspects relating to methods or apparatus for disinfecting or sterilising materials or objects
- A61L2202/20—Targets to be treated
- A61L2202/21—Pharmaceuticals, e.g. medicaments, artificial body parts
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- Botany (AREA)
- Food Science & Technology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nanotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Medical Informatics (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Alternative & Traditional Medicine (AREA)
- Biochemistry (AREA)
- Inorganic Chemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
Abstract
本发明公开了一种红色零价单质纳米硒口服液及其制备方法和应用。一种红色零价单质纳米硒口服液,制备原料包括:零价纳米硒;零价纳米硒,来源于乳酸菌还原所得和谷胱蛋白还原所得中的至少一种;有机硒肽;有机硒肽,来源于富硒黄芪的发酵产物;富硒黄芪,培养过程中,培养基体中包括亚硒酸钠水溶液。本发明的纳米硒口服液,通过将零价纳米硒和有机硒肽结合,并调整上述两种原料的来源,降低了上述口服液中硒的生物毒性,提升了其生物活性,使其更有利于辅助治疗癌症病人。
Description
技术领域
本发明属于保健品技术领域,具体涉及一种红色零价单质纳米硒口服液及其制备方 法和应用。
背景技术
现代医学研究表明,硒在维持心血管系统正常结构和功能上起着重要作用,缺硒是 导致癌症、肿瘤、心肌病、冠心病、高血压、糖尿病等高发的重要因素。补硒可有效提 升机体对上述疾病的抗性。
自然界中,硒的存在形式主要有无机硒和有机硒两种。
其中有机硒是人从自然界中摄取硒的主要来源,主要有硒代胱氨酸、硒蛋氨酸、甲基硒半胱氨酸。生物有机硒安全性高、不易发生中毒、易被人体吸收、补硒效率高。但 是现有生物有机硒的制备方法较为复杂。
无机硒盐是我们生物圈中最常见的硒形式,主要有硒酸盐离子(SeO4 2-)和亚硒酸盐离 子(SeO3 3-)两种,在生物体补硒领域中,无机硒生物有效性低、毒性大,中毒量与需要量 之间范围小,在生物体补硒的发展历史中,不乏硒中毒的案例,因此硒酸盐、亚硒酸盐,已被严格限制作为生物体补硒的来源。
零价纳米硒是一种不溶金属化合物,本质上虽属于无机硒,但是根据其尺寸的变化, 可显示红色、灰色等各种物理特性,化学特性也与常规无机硒(含硒盐)差异较大,有研究表明,相比其他价态的硒,红色零价纳米硒的具有毒性更低、更有利于生物体的吸 收、利用等优点。
但是,现在市场上的口服类补硒剂的含硒量,仅满足日常补硒的要求,若增加含硒量,仍有可能出现硒中毒的危险,因此无法辅助治疗癌症病人。
发明内容
本发明旨在至少解决上述现有技术中存在的技术问题之一。为此,本发明提出一种 红色零价单质纳米硒口服液,通过将零价纳米硒和有机硒肽结合,并调整上述两种原料的来源,降低了上述口服液中硒的生物毒性,提升了其生物活性,使其更有利于辅助治 疗癌症病人。
本发明还提出一种上述红色零价单质纳米硒口服液的制备方法。
本发明还提出一种上述红色零价单质纳米硒口服液在制备提升人体免疫力药物中 的应用。
根据本发明的一个方面,提出了一种红色零价单质纳米硒口服液,制备原料包括:
零价纳米硒;所述零价纳米硒,包括乳酸菌还原零价纳米硒和谷胱蛋白还原零价纳 米硒中的至少一种;
有机硒肽;所述有机硒肽为富硒黄芪发酵有机硒肽;
所述富硒黄芪,培养过程中,培养基体中包括亚硒酸钠水溶液。
根据本发明的一种优选的实施方式,至少具有以下有益效果:
(1)本发明提供的红色零价单质纳米硒口服液中,硒的存在形式为有机硒肽和零价纳米硒;相对于无机硒(亚硒酸盐),本发明中的硒,毒性低、活性高;
相对于大分子蛋白硒,本发明中的硒尺寸更小、更容易被基体吸收。
(2)本发明中的零价纳米硒,来源于乳酸菌还原所得和谷胱蛋白还原所得中的至少一种,因此本来不稳定的零价纳米硒,可与乳酸菌中的活性生物材料/谷胱蛋白相结合,提升其保存稳定性,并同时提升其生物活性和在生物体中的吸收性。
(3)本发明提供的有机硒肽,来源于富硒黄芪的发酵产物;黄芪中本就容易富集硒,以含有亚硒酸钠水溶液的基体培养后,其中的硒含量进一步提升;此外,富硒黄芪 的发酵过程中,不仅可获得有机硒肽,还可获得黄芪多糖等黄芪中的药用成分,上述药 用成分可有效提升人体的免疫力,因此,本发明所得红色零价单质纳米硒口服液,不仅 具有补硒、抗癌的作用,还兼具提升人体免疫力的作用。
在本发明的一些实施方式中,所述红色零价单质纳米硒口服液中,所述零价纳米硒 的浓度为10~100μg/ml。
在本发明的一些实施方式中,所述红色零价单质纳米硒口服液中,所述有机硒肽的 浓度为6~50μg/ml。
在本发明的一些实施方式中,所述红色零价单质纳米硒口服液中,所述零价纳米硒, 制备方法包括以下步骤:
A1.在含有亚硒酸钠的乳酸菌液体培养基中,接种1.0×104~1.0×106cfu/ml的乳酸菌, 并于30~40℃温度下培养;
A2.收集步骤A1所得培养液,离心后,得包含有所述乳酸菌的沉淀物;
A3.收集步骤A2所得沉淀物,破碎、分离除去所述乳酸菌细胞碎片、并洗涤后,即得所述零价纳米硒。
在本发明的一些实施方式中,步骤A1中,按重量份计,所述乳酸菌液体培养基中,含有16~18份葡萄糖、17~18份蛋白胨、6~9份牛肉膏、4~5份氯化钠以及1.5~20份亚 硒酸钠。
在本发明的一些实施方式中,步骤A1中,所述培养,压力范围约为0.04MPa。
在本发明的一些实施方式中,步骤A1中,所述乳酸菌液体培养基,pH为5.5~7.5。
在本发明的一些实施方式中,所述零价纳米硒的制备方法中,还包括在步骤A1和A2之间,向步骤A1所得体系中添加牛清蛋白和半胱氨酸;所述牛清蛋白可以作为分散 剂;所述半胱氨酸可作为还原剂,将步骤A1中,未还原完全的亚硒酸钠还原至零价纳 米硒;进一步降低了所述红色零价单质纳米硒口服液中所残留的强毒性亚硒酸钠,也降 低了排放废水中毒性亚硒酸钠的含量。
在本发明的一些实施方式中,步骤A3中,所述破碎,包括依次进行的冷冻、研磨、破壁。
在本发明的一些实施方式中,所述破壁,采用破壁机进行。
在本发明的一些实施方式中,步骤A3中,除去所述乳酸菌细胞碎片,包括依次进行的,将破壁后的材料与十二烷基磺酸钠的水溶液混合、离心上述水溶液,得固体。
在本发明的一些实施方式中,所述零价纳米硒,制备完成后,为确保其不变质,在约4℃的温度,以水的悬浊液形式保存。
在本发明的一些实施方式中,所述富硒黄芪,培养过程中,每季度浇灌一次亚硒酸钠水溶液。
在本发明的一些实施方式中,所述富硒黄芪,培养过程中,按所述亚硒酸钠的质量计,每季度所述亚硒酸钠水溶液的浇灌量为,0.4~150kg/亩。
在本发明的一些实施方式中,所述有机硒肽,制备方法包括以下步骤:
B1.将所述富硒黄芪粉碎,并添加复合酶进行发酵,得第一发酵液和发酵渣;
B2.在所述发酵渣中接种所述乳酸菌,发酵后,得第二发酵液;
B3.将所述第一发酵液和第二发酵液合并、并进行微生物细胞破碎、除去杂质后,得 所述有机硒肽。
在本发明的一些实施方式中,步骤B1中,所述富硒黄芪可以为干燥富硒黄芪也可以为新鲜富硒黄芪;其中新鲜富硒黄芪中的黄芪多糖含量更高。
在本发明的一些实施方式中,步骤B1中,所述复合酶,为纤维素酶和果胶酶以1:1的比例混合所得。
在本发明的一些实施方式中,步骤B2中,所述乳酸菌,接种量为 1.0×105~1.0×108cfu/ml。
在本发明的一些实施方式中,步骤B2中,所述第二发酵液,发酵条件为温度:30~35℃; 通气量为0.01~20%;压力为0.03~0.04MPa。
在本发明的一些实施方式中,所述红色零价单质纳米硒口服液中,还可以包括口味 调节剂,所述口味调节剂包括食用盐、枸杞糖、蜂蜜和琼脂中的至少一种。
所述枸杞糖,也具有提升人体免疫力的作用。
在本发明的一些实施方式中,所述红色零价单质纳米硒口服液中,还可以包括药食 同源药材。
所述药食同源药材选自覆盆子提取物和沙棘提取物中的至少一种。
所述覆盆子提取物的制备方法,包括将覆盆子粉末按照10~30ml/g料液比与50~90wt% 乙醇混合,并于40~60℃提取10~60min后,于-30~-60℃下冻干所得提取液。
所述沙棘提取物的制备方法,包括将沙棘果的粉和50~95wt%的乙醇,按5~20ml/g 的比例混合后,常温提取0.5~3h后,于-30~-60℃下冻干所得提取液。
根据本发明的再一个方面,提出了所述红色零价单质纳米硒口服液的制备方法,包 括以下步骤:
S1.将所述零价纳米硒和有机硒肽混合后,进行蒸汽加压灭菌;
S2.将步骤S1所得液体进行无菌灌装后,即得所述红色零价单质纳米硒口服液。
在本发明的一些实施方式中,步骤S1中,所述蒸汽加压灭菌,温度为105~115℃。
在本发明的一些实施方式中,步骤S1中,所述蒸汽加压灭菌,时间为15~30min。
在本发明的一些实施方式中,步骤S1中,所述蒸汽加压灭菌,压力为55~65kPa。
由于本发明提供的红色零价单质纳米硒口服液中包含黄芪多糖、有机硒肽(一种结 合了硒的肽链)等易失活材料,因此选用上述条件进行蒸汽加压灭菌,能保证菌类的灭活,进而延长所述红色零价单质纳米硒口服液的保质期,同时也能保证黄芪多糖等生物 活性营养物质不致失活。
根据本发明的再一个方面,提出了所述红色零价单质纳米硒口服液在制备提升人体 免疫力药物中的应用。
若无特殊说明,本发明所用乳酸菌,购自生物资源保存与研究中心。
具体实施方式
以下将结合实施例对本发明的构思及产生的技术效果进行清楚、完整地描述,以充 分地理解本发明的目的、特征和效果。显然,所描述的实施例只是本发明的一部分实施例,而不是全部实施例,基于本发明的实施例,本领域的技术人员在不付出创造性劳动 的前提下所获得的其他实施例,均属于本发明保护的范围。
实施例1
本实施例制备了一种红色零价单质纳米硒口服液,具体过程为:
D1.在含有亚硒酸钠的乳酸菌液体培养基中,接种1.0×105cfu/ml的乳酸菌,并于35℃ 温度下培养48h,培养过程中压力约为0.04MPa;其中液体培养基的成分为:17g葡萄糖、17g蛋白胨、9g牛肉膏、4g氯化钠以及2g亚硒酸钠,pH约为7;
D2.向步骤D1所得体系中,加入2g半胱氨酸和2g牛清蛋白,继续保温2h;
D3.收集步骤D2所得培养液,离心(转速8000rpm,5min)后,得包含有乳酸菌的 沉淀物;
D4.收集步骤D3所得沉淀物,破碎(沉淀物分散至生理盐水中后,冷冻、研磨)、 分离除去乳酸菌细胞碎片(离心取沉淀物)、并洗涤(透析至透析液中亚硒酸根的检测 限低于ICP-AES的检测限)后,将上述透析体系离心,并将所得固体重新分散保存至约 4℃的水中,得零价纳米硒悬浮液;
D5.将富硒黄芪粉碎,并添加纤维素酶和果胶酶(1:1质量比)进行发酵,以溶解富硒黄芩中的细胞壁和果胶,以使其中的营养物质更好的溶出,得第一发酵液和发酵渣;
D6.在发酵渣中接种乳酸菌,接种量为1.0×107cfu/ml,发酵条件为温度:30℃;通气 量为5%;压力为0.03MPa;发酵48h后,固液分离(离心或过滤,本实施例采用过滤), 得第二发酵液;
D7.将第一发酵液和第二发酵液合并、并进行微生物细胞破碎(破壁机)、除去杂质后(过滤,去除大颗粒),得有机硒肽;
D8.按照60μg/ml零价纳米硒、40μg/ml有机硒肽的比例,将步骤D4所得零价纳米硒悬浮液、步骤D7所得有机硒肽和水混合;
D9.将步骤D8所得体系于105℃、55kPa的压力下,灭菌20min,灌装后即得纳米硒口服液。
本实施例所有步骤均在无菌条件下操作进行,所用试剂,包括水,均进行了灭菌处理。
实施例2
本实施例制备了一种红色零价单质纳米硒口服液,具体过程为:
D1.在含有亚硒酸钠的乳酸菌液体培养基中,接种1.0×105cfu/ml的乳酸菌,并于35℃ 温度下培养48h,培养过程中压力约为0.04MPa;其中液体培养基的成分为:17g葡萄糖、17g蛋白胨、9g牛肉膏、4g氯化钠以及2g亚硒酸钠,pH约为7;
D2.向步骤D1所得体系中,加入2g半胱氨酸和2g牛清蛋白,继续保温2h;
D3.收集步骤D2所得培养液,离心(转速8000rpm,5min)后,得包含有乳酸菌的 沉淀物;
D4.收集步骤D3所得沉淀物,破碎(沉淀物分散至生理盐水中后,冷冻、研磨)、 分离除去乳酸菌细胞碎片(离心取沉淀物)、并洗涤(透析至透析液中亚硒酸根的检测 限低于ICP-AES的检测限)后,将上述透析体系离心,并将所得固体重新分散保存至约 4℃的水中,得零价纳米硒悬浮液;
D5.将富硒黄芪粉碎,并添加纤维素酶和果胶酶(1:1质量比)进行发酵,以溶解富硒黄芩中的细胞壁和果胶,以使其中的营养物质更好的溶出,得第一发酵液和发酵渣;
D6.在发酵渣中接种乳酸菌,接种量为1.0×107cfu/ml,发酵条件为温度:30℃;通气 量为5%;压力为0.03MPa;发酵48h后,固液分离(离心或过滤,本实施例采用过滤), 得第二发酵液;
D7.将第一发酵液和第二发酵液合并、并进行微生物细胞破碎(破壁机)、除去杂质后(过滤,去除大颗粒),得有机硒肽;
D8.将覆盆子粉末与90wt%乙醇按照30ml/g的比例混合后,在60℃浸提30min后,将浸提液于-50℃冷冻干燥30min,得覆盆子提取物;
D9.将沙棘粉末与90wt%乙醇按照10ml/g的比例混合后,常温提取1h,之后将所得提取液于-50℃冷冻干燥30min,得沙棘提取物;
D10.按照60μg/ml零价纳米硒、40μg/ml有机硒肽和3μg/ml覆盆子提取物、3μg/ml沙棘提取物和3μg/ml蜂蜜的比例,将步骤D4所得零价纳米硒悬浮液、步骤D7所得有 机硒肽、步骤D8所得覆盆子提取物和步骤D9所得沙棘提取物和水混合;
D11.将步骤D9所得体系于105℃、55kPa的压力下,灭菌20min,灌装后即得红色 零价单质纳米硒口服液。
本实施例所有步骤均在无菌条件下操作进行,所用试剂,包括水,均进行了灭菌处理。
对比例1
本对比例制备了一种红色零价单质纳米硒口服液,具体过程与实施例1的区别为:
(1)不包括步骤D1~D4;
(2)步骤D8中,不包括零价纳米硒,直接按照100μg/ml有机硒肽的比例配置有 机硒肽和水的混合液。
对比例2
本对比例制备了一种红色零价单质纳米硒口服液,具体过程与实施例1的区别为:
(1)不包括步骤D5~D7;
(2)步骤D8中,不包括有机硒肽,直接按照100μg/ml零价纳米硒的比例配置零 价纳米硒和水的混合液。
试验例
本试验例的第一方面测试了实施例和对比例所得红色零价单质纳米硒口服液的性能, 具体以目测法测试了其外观、参照GB5009.12.2017第一法测试了其中的主要元素含量。 测试结果为:实施例1~2和对比例2所得红色零价单质纳米硒口服液颜色为红色,质地均匀;实施例1~2以及对比例1~2所得红色零价单质纳米硒口服液中金属元素含量相当,具体如表1所示:
表1实施例2所得红色零价单质纳米硒口服液中主要元素含量(单位mg/l)
从表1结果可知,本发明提供的红色零价单质纳米硒口服液,硒含量与设计含量相当,同时富含人体所需微量元素,而对人体有毒有害的元素,则几乎不包含,因此在具 有高营养的基础上,降低了毒性。
本试验例测试了实施例和对比例制备的红色零价单质纳米硒口服液对H22肝细胞增 殖的抑制性能。其中具体过程为:
取40只健康小鼠(20~25g),取4只作为对照组,另外36均分为12组,分别命名 为实施例1一组、实施例1二组、实施例1三组、实施例1四组、对比例1一~四组, 以及对比例2一~四组;
对40只小鼠分别腹腔接种106个H22肝癌细胞(购自上海斯莱克实验动物中心);
紧接着喂食对照组小鼠生理盐水;喂食实验组不同剂量的红色零价单质纳米硒口服 液(按零价纳米硒和有机硒肽质量和与小鼠体重之比计,每组每日摄入量分别为0.1mg/kg、0.2mg/kg、0.5mg/kg、0.7mg/kg);具体硒喂养量如表2所示;
表2实验组小鼠红色零价单质纳米硒口服液喂养情况表
连续喂养7天,其中对照组和实验组除摄入红色零价单质纳米硒口服液量不同外,采用相同的喂食;
将实验组和对照组小鼠处死,收集腹水,细胞计数。
结果显示:
本测试例采用的40只小鼠,在喂养过程中均未出现中毒现象,说明本发明制备的零 价纳米硒、有机硒肽或者上述两种形式硒混合形成的红色零价单质纳米硒口服液,均具有较低的生物毒性;
与对照组小鼠相比,实验组小鼠(包括实施例1一~四组、对比例1一~四组、对比例2一~四组),腹腔内细胞外GPx、GR和GST总活力均有一定降低,说明实施例和对 比例所得红色零价单质纳米硒口服液均可抑制H22细胞的增殖;
与对比例1~2共8组实验组相比,本发明实施例1的四组实验组中,小鼠腹腔内细胞外GPx、GR和GST总活力更低,说明本发明中有机硒肽和零价纳米硒发生了协同作 用,对H22肝癌细胞的抑制更为明显。
上面对本发明实施例作了详细说明,但是本发明不限于上述实施例,在所属技术领 域普通技术人员所具备的知识范围内,还可以在不脱离本发明宗旨的前提下作出各种变 化。此外,在不冲突的情况下,本发明的实施例及实施例中的特征可以相互组合。
Claims (10)
1.一种红色零价单质纳米硒口服液,其特征在于,制备原料包括:
零价纳米硒;所述零价纳米硒,包括乳酸菌还原零价纳米硒和谷胱蛋白还原零价纳米硒中的至少一种;
有机硒肽;所述有机硒肽为富硒黄芪发酵有机硒肽;
所述富硒黄芪,培养过程中,培养基体中包括亚硒酸钠水溶液。
2.根据权利要求1所述的红色零价单质纳米硒口服液,其特征在于,所述红色零价单质纳米硒口服液中,所述零价纳米硒的浓度为10~100μg/ml;优选的,所述有机硒肽的浓度为6~50μg/ml。
3.根据权利要求1所述的红色零价单质纳米硒口服液,其特征在于,所述红色零价单质零价纳米硒,制备方法包括以下步骤:
A1.在含有亚硒酸钠的乳酸菌液体培养基中,接种1.0×104~1.0×106cfu/ml的乳酸菌,并于30~40℃温度下培养;
A2.收集步骤A1所得培养液,离心后,得包含有所述乳酸菌的沉淀物;
A3.收集步骤A2所得沉淀物,破碎、分离除去所述乳酸菌细胞碎片、并洗涤后,即得所述零价纳米硒。
4.根据权利要求3所述的红色零价单质纳米硒口服液,其特征在于,步骤A3中,所述破碎,包括依次进行的冷冻、研磨、破壁;优选的,除去所述乳酸菌细胞碎片,包括依次进行的,将破壁后的材料与十二烷基磺酸钠的水溶液混合、离心上述水溶液,得固体。
5.根据权利要求1所述的红色零价单质纳米硒口服液,其特征在于,所述富硒黄芪,培养过程中,每季度浇灌一次亚硒酸钠水溶液;优选的,按所述亚硒酸钠的质量计,所述亚硒酸钠水溶液的浇灌量为,0.4~150kg/亩。
6.根据权利要求1所述的红色零价单质纳米硒口服液,其特征在于,所述有机硒肽,制备方法包括以下步骤:
B1.将所述富硒黄芪粉碎,并添加复合酶进行发酵,得第一发酵液和发酵渣;
B2.在所述发酵渣中接种所述乳酸菌,发酵后,得第二发酵液;
B3.将所述第一发酵液和第二发酵液合并、并进行微生物细胞破碎、除去杂质后,得所述有机硒肽。
7.根据权利要求6所述的红色零价单质纳米硒口服液,其特征在于,步骤B2中,所述乳酸菌,接种量为1.0×105~1.0×108cfu/ml;优选的,所述第二发酵液,发酵条件为温度:30~35℃;通气量为0.01~20%;压力为0.03~0.04MPa。
8.一种如权利要求1~7任一项所述红色零价单质纳米硒口服液的制备方法,其特征在于,包括以下步骤:
S1.将所述零价纳米硒和有机硒肽混合后,进行蒸汽加压灭菌;
S2.将步骤S1所得液体进行无菌灌装后,即得所述红色零价单质纳米硒口服液。
9.根据权利要求8所述的红色零价单质纳米硒口服液的制备方法,其特征在于,所述蒸汽加压灭菌,温度为105~115℃;优选的,时间为15~30min;进一步优选的,压力为55~65kPa。
10.一种如权利要求1~7任一项所述红色零价单质纳米硒口服液在制备提升人体免疫力药物中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110880225.0A CN113975367A (zh) | 2021-08-02 | 2021-08-02 | 一种红色零价单质纳米硒口服液及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110880225.0A CN113975367A (zh) | 2021-08-02 | 2021-08-02 | 一种红色零价单质纳米硒口服液及其制备方法和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113975367A true CN113975367A (zh) | 2022-01-28 |
Family
ID=79735122
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110880225.0A Pending CN113975367A (zh) | 2021-08-02 | 2021-08-02 | 一种红色零价单质纳米硒口服液及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113975367A (zh) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104431428A (zh) * | 2014-11-13 | 2015-03-25 | 苏州市相城区盛胡特种养殖专业合作社 | 一种提高水产品免疫力的营养调节剂 |
CN107183400A (zh) * | 2017-05-26 | 2017-09-22 | 广西广济生命科技有限公司 | 一种蛋鸡饲料 |
CN109007139A (zh) * | 2018-06-15 | 2018-12-18 | 刘汉国 | 一种有机硒、硒蛋白以及硒肽硒氨基酸混合物提取方法 |
CN109770363A (zh) * | 2019-03-15 | 2019-05-21 | 陕西科技大学 | 一种纳米硒益生菌冻干粉及其制备方法 |
CN111494451A (zh) * | 2020-05-14 | 2020-08-07 | 湖北民族大学 | 一种绞股蓝生物活性硒口服液及其制备方法 |
CN113069463A (zh) * | 2021-04-09 | 2021-07-06 | 甘肃中医药大学 | 富硒黄芪皂苷在减缓软骨细胞退变上的应用 |
-
2021
- 2021-08-02 CN CN202110880225.0A patent/CN113975367A/zh active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104431428A (zh) * | 2014-11-13 | 2015-03-25 | 苏州市相城区盛胡特种养殖专业合作社 | 一种提高水产品免疫力的营养调节剂 |
CN107183400A (zh) * | 2017-05-26 | 2017-09-22 | 广西广济生命科技有限公司 | 一种蛋鸡饲料 |
CN109007139A (zh) * | 2018-06-15 | 2018-12-18 | 刘汉国 | 一种有机硒、硒蛋白以及硒肽硒氨基酸混合物提取方法 |
CN109770363A (zh) * | 2019-03-15 | 2019-05-21 | 陕西科技大学 | 一种纳米硒益生菌冻干粉及其制备方法 |
CN111494451A (zh) * | 2020-05-14 | 2020-08-07 | 湖北民族大学 | 一种绞股蓝生物活性硒口服液及其制备方法 |
CN113069463A (zh) * | 2021-04-09 | 2021-07-06 | 甘肃中医药大学 | 富硒黄芪皂苷在减缓软骨细胞退变上的应用 |
Non-Patent Citations (2)
Title |
---|
张羽竹: "乳酸菌制备硒纳米颗粒的条件优化及分子机制初探", 中国优秀硕士学位论文全文数据库 基础科学辑, no. 02 * |
王鹏飞: "黄芪发酵工艺及发酵制品质量评价研究", 中国优秀硕士学位论文全文数据库 医药卫生科技辑, no. 07, pages 32 - 33 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108753874A (zh) | 一种小分子活性肽新型螺旋藻粉的制备方法 | |
CN107549817B (zh) | 一种辣木天然有机钙及其制备方法 | |
CN106551378A (zh) | 一种益生菌发酵蛹虫草的组合物及其制备方法和应用 | |
CN112430546A (zh) | 莱茵衣藻、莱茵衣藻粉的异氧发酵制备方法及应用 | |
CN105768106A (zh) | 一种有助于肝营养改善的功能性食品 | |
CN109452634B (zh) | 真菌共生发酵降血糖辣木及其制备方法 | |
CN110656151A (zh) | 一种提高海参补肾壮阳功效的方法 | |
CN113975367A (zh) | 一种红色零价单质纳米硒口服液及其制备方法和应用 | |
CN110590908A (zh) | 一种小带鱼源抗菌肽添加剂及其制备方法 | |
CN115005436A (zh) | 一种白芸豆发酵提取物及其制备方法和降糖降压的用途 | |
WO2021077788A1 (zh) | 一株解脂耶式酵母及其在制备低糖低脂椰蓉营养粉中的用途 | |
CN110974849B (zh) | 一种具有降血糖活性的复合海参提取物及制备方法与应用 | |
CN106260359A (zh) | 一种雪莲培养物组合物灵芝茶及其制备方法 | |
CN111449241A (zh) | 一种提高海参皂甙提取液抗氧化能力的方法 | |
CN110547397A (zh) | 一种肿瘤康复营养代餐食品及其制备方法 | |
CN109771452A (zh) | 虎奶菇提取物在制备治疗肿瘤药物中的应用 | |
JP2714663B2 (ja) | 腸内有益菌増殖促進剤 | |
CN113491331B (zh) | 一种海藻多糖组合物与复合果汁混合发酵粉及其制备方法与应用 | |
CN109355335B (zh) | 芹菜籽发酵制备的降血脂肽的提取方法 | |
CN115814016B (zh) | 一种凝结芽孢杆菌和大蒜皮的组合物及其应用 | |
CN111265627B (zh) | 一种调节肠道菌群的海参多糖组合物及其制备方法和应用 | |
CN105255651B (zh) | 一种小球藻多肽酒及其制备方法 | |
CN111494425A (zh) | 一种提高鲍灵素提取液抗癌免疫增强功效的方法 | |
CN105995322B (zh) | 一种具有清除体内垃圾、营养机体作用的富有机硒活性水 | |
CN114158667A (zh) | 一种北冬虫夏草多糖饮料及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |